Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trialAndrés Poveda, Nicolas Pécuchet, Richard T. Penson et al.|The Lancet Oncology|2021Cited by 412
ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016Christian Dittrich, Rainer Kunstfeld, Michael P. Kosty et al.|ESMO Open|2016Cited by 129